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Cav1.2 L-type calcium channels are essential in heart and smooth muscle contraction. Rat Cav1.2 gene contains 11 alternatively spliced exons
(1a, 1, 8a, 8, 9⁎, 21, 22, 31, 32, 32-6nt and 33) which can be assorted to generate a large number of functionally distinct splice variants. Until now,
it is unknown whether the utilization of these alternatively spliced exons is altered in the hypertrophied hearts of hypertensive rats. By comparing
the assortments of these 11 exons in full-length Cav1.2 transcripts derived from Spontaneously Hypertensive Rats (SHRs) and Wistar Kyoto Rats
(WKYs) hearts, we found that the inclusion of Cav1.2 alternative exons was significantly different between the two rats both at individual loci and
in combinatorial arrangements. Functional characterizations of three Cav1.2 channel splice variants that were identified to be significantly altered
in SHR hypertrophied cardiomyocytes demonstrated distinct whole-cell electrophysiological properties when expressed in HEK 293 cells.
Interestingly, aberrant splice variants which included or excluded both mutually exclusive exons 21/22 or exons 31/32 were found to be increased
in hypertensive rats. Two aberrant splice variants that included both exons 21 and 22 were found to be unable to conduct currents even though they
expressed proteins with the predicted molecular mass. Characterization of one of the aberrant splice variants showed that it exerted a dominant
negative effect on the functional Cav1.2 channels when co-expressed in HEK293 cells. The altered combinatorial splicing profiles of Cav1.2
transcripts identified in SHR hearts provide a different and new perspective in understanding the possible role of molecular remodeling of Cav1.2
channels in cardiac hypertrophy as a consequence of hypertension.
© 2007 Elsevier B.V. All rights reserved.Keywords: Alternative splicing; Cav1.2; Voltage gated calcium channel; Spontaneously Hypertensive Rat; Hypertension; Hypertrophied heart1. Introduction
L-type (Cav1.2) voltage-gated calcium channels play essen-
tial roles in excitation–contraction coupling in heart and in
maintaining the cardiac action potentials [1–4]. Physiologically,
the pore-forming Cav1.2 subunit has been shown to undergo
extensive alternative splicing to generate many variations sup-
porting distinctive and diverse functions and pharmacological⁎ Corresponding author. Department of Physiology, Yong Loo Lin School of
Medicine, National University of Singapore, Blk MD9, 2 Medical Drive,
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doi:10.1016/j.bbamcr.2007.11.003properties [5–13]. Pathologically, Gidh-Jain et al. reported that
there was a significant increase in mRNA level of the fetal
isoform containing alternatively spliced exon 31, encoding for
IVS3 segment of Cav1.2 subunit, in rodent non-infarcted
myocardium during left ventricular remodeling [14]. Yang et
al. also reported a switch in the distribution of the mutually
exclusive exons 31/32 in human heart failure [15]. Recently, in
human arterial vascular smooth muscle cells that have under-
gone atherosclerosis, Tiwari et al. reported that exons 9a (also
named as exon 9⁎), 21/22, and 41A were altered [16]. These
studies strongly suggest that alternative splicing of Cav1.2
subunit may be generally affected in pathological conditions.
The gene encoding humanCav1.2 subunit,CACNA1C, is huge
and spans more than 500 kb in the human genome and contains at
Table 1
The blood pressures, ratios of heart weight-to-body weight and left ventricle
weight-to-body weight of SHRs and WKYs
Rat
strains
Systolic blood
pressure (mmHg)
Heart weight/body
weight (mg/g)
Left ventricle
weight/body
weight (mg/g)
3-month WKY 108±8.2 (n=5) 3.1±0.10 (n=3) –
3-month SHR 175±6.9 (n=5)⁎⁎ 3.7±0.12 (n=3)⁎ –
4.5-month WKY 127±3.8 (n=5) 2.9±0.11 (n=5) 2.0±0.26 (n=5)
4.5-month SHR 187±7.6 (n=5)⁎⁎ 3.6±0.16 (n=5)⁎⁎ 2.7±0.30 (n=5)⁎⁎
8-month WKY 123±6.3 (n=6) 3.0±0.05 (n=6) –
8-month SHR 193±8.2 (n=6)⁎⁎ 3.6±0.08 (n=6)⁎⁎ –
Student's t-test was applied in comparing the blood pressures and ratios of heart
weight-to-body weight of age-matched 3-, 4.5- and 8-month old SHRs and
WKYs, and ratios of left ventricle weight-to-body weight of 4.5-month old SHRs
and WKYs. n is the number of samples (rats or ventricles) tested. ⁎, pb0.05;
⁎⁎, pb0.01.
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52 exons and 11 of them are alternatively spliced exons (Fig. 1).
Technically, it is difficult to obtain a large number of full-length
transcripts for this huge gene and to examine the changes of
multiple alternatively spliced exons in each full-length cDNA
clone. Therefore, while the changes in levels of inclusion of single
alternatively spliced exons have been examined, the dynamic
changes of multiple alternatively spliced exons in combination
across the entire full-length Cav1.2 transcripts have not been
investigated in pathological tissues. Here, by using long-range
reverse transcriptase PCR (RT-PCR), hundreds of full-length
Cav1.2 cDNA clones were generated from mRNA isolated from
Spontaneously Hypertensive Rats (SHRs) hypertrophied hearts
and normotensive Wistar Kyoto Rats (WKYs) hearts. These
clones were then screened individually to profile their alterna-
tive splicing patterns.
Three different groups of full-length Cav1.2 cDNAs with
distinct alternative exon combinatorial profiles were identified
in rat heart and aorta in our previous study [19]. In heart, two
distinct groups of Cav1.2 cDNAs designated heart 1a–50 and
heart 1–50 were generated from alternate exon 1a and exon 1. In
this study, we found that the alternative splicing patterns of the
Cav1.2 gene in SHR hearts were significantly changed both at
individual loci and in combinatorial arrangements in both
groups of heart 1a–50 and heart 1–50 Cav1.2 cDNAs. Func-
tional characterization of several Cav1.2 splice variants up-
regulated in hypertension by whole-cell patch clamp recordings
demonstrated altered electrophysiological properties in compar-
ison with the dominant splice variant from WKY controls.
2. Materials and methods
2.1. Measurement of blood pressures, body weight and heart weight of
SHRs and WKYs
The blood pressures of SHRs and WKYs (the Animal Resource Center,
Canning Vale, WA 6970, Australia) were measured by the tail-cuff method
(ML125 system, Powerlab, ADInstruments). For assessment of cardiac
hypertrophy, the whole animals, hearts and ventricles from SHRs and WKYs
were weighed and the heart/body or left ventricle/body weight ratios were
determined.Fig. 1. Diagrammatic representation of 11 alternatively spliced exons of the rat
Cav1.2 subunit. There are 2 optional exons indicated by black boxes (exons 9⁎
and 33) and 9 putative mutually exclusive exons indicated by hatched boxes
(exons 1, 1a, 8, 8a, 21, 22, 31, 32 and 32-6nt).2.2. Total RNA extraction, first strand Cav1.2 cDNA synthesis and
real-time PCR to determine the ratios of exon 1a and exon 1
containing Cav1.2 cDNA
Total RNA was extracted from left ventricles of five 4.5-month SHRs and
five 4.5-month WKYs (3 males and 2 females in each groups) individually by
RNeasy® Kits (QIAGEN Science, Maryland, USA). Reverse transcription for
each rat RNA sample was separately carried out with SUPERSCRIPT II
(Invitrogen, CA, USA). The primer for first strand Cav1.2 cDNA synthesis is
complementary to 3′-untranslated regions of rat Cav1.2 gene (primer No. 6,
supplemental Table 1). TaqMan quantitative real-time PCR for determining the
ratios of exon 1a to exon 1 expression in rat ventricles were carried out as
described in the previous study [19]. All the animal work has been approved by
and done in accordance with the Institutional Animal Care and Use Committee
(IACUC) guidelines of the National University of Singapore.
2.3. Generation of full-length heart 1a–50 and heart 1–50 Cav1.2
cDNAs from SHRs and WKYs
The PCR reactions were carried out to amplify the full-length rat Cav1.2
cDNAs from exon 1a to exon 50 (primer Nos. 5 and 6, Supplemental Table
S1) and from exon 1 to exon 50 (primer Nos. 7 and 8, Supplemental Table
S1) using total RNAs isolated from SHR or WKY rat ventricles (Fig. 2A).
The sequences of all the primers used in this study are indicated in
Supplementary Table S1. Negative controls were done in parallel using RNA
that was subject to reverse transcription reaction but without the addition of
reverse transcriptase. PCR products from 5 SHRs and 5 WKYs with similar
band intensities were pooled together, cloned into pCR®-XL-TOPO® vectors
(Invitrogen™) and transformed into DH10B Escherichia coli. After
screening approximately 3000 bacterial colonies by colony PCR method
(exon 6–12, primer Nos. 13 and 14; and exon 44–47, primer Nos. 25 and
26, Supplemental Table S1), a total of 402 colonies (216 colonies from
SHRs and 186 colonies from WKYs) representing 4 groups of full-length
cDNAs were isolated. Each group of full-length Cav1.2 cDNAs contained
92 to 116 clones. These full-length Cav1.2 cDNAs were designated as SHR
heart 1a–50, SHR heart 1–50, WKY heart 1a–50, and WKY heart 1–50
respectively.
2.4. Exon-specific PCR to identify inclusion or exclusion of
alternatively spliced exons in Cav1.2 cDNA clones
For each Cav1.2 cDNA clone in SHR heart 1a–50, SHR heart 1–50, WKY
heart 1a–50, and WKY heart 1–50, eight PCR reactions were carried out to
identify inclusion or exclusion of specific alternatively spliced exons in the
clone. The detailed procedures of exon-specific colony PCR are presented in
Supplementary Data.
Fig. 2. A. Exemplars of full-length PCR for heart 1a–50 and heart 1–50 from
two 4.5-month SHR ventricles. Lanes 1 and 2 show the PCR results of heart 1a–
50 reaction (primer Nos. 5 and 6; Supplemental Table S2) and lanes 3 and 4
show the PCR results of heart 1–50 reaction (primer Nos. 7 and 8, Supplemental
Table S2). The expected PCR product is 6.5 kb for heart 1a–50 and 6.7 kb for
heart 1–50. “−ve” indicates the negative control PCRs using corresponding
RNAwithout reverse transcriptase treatment. B. Exon 8a specific PCR reactions
(primer Nos. 9 and 10) were carried out in 4.5-month SHR and WKY heart 1a–
50 cDNA containing colonies to identify the percentages of inclusions of exon
8a and exon 9⁎. Upper panel is the colony PCR results for SHR heart 1a–50
cDNAs and lower panel is for WKY heart 1a–50 cDNAs. The sequencing result
confirmed there was inclusion of exon 9⁎ in the higher band and without exon
9⁎ in the lower band. The negative controls using untransformed colonies as
templates are indicated as “−ve”. C. The percentages of nine individual
alternatively spliced exons identified in 4.5-month SHR and WKY heart 1a–50
cDNAs were compared. n=100 clones for SHR heart 1a–50 and n=92 clones
for WKY heart 1a–50. Exon 9⁎ was up-regulated approximately 3.7 times from
3% in WKYs to 11% in SHRs (⁎, pb0.05, z-test). The exact percentages of the
alternatively spliced exons are presented in Supplemental Table S2.
Table 2
The proportions of splice variants in heart 1a–50 cDNAs from 4.5-month SHRs
and WKYs
WKY heart 1a–50 n=92 SHR heart 1a–50 n=100
11 variants Percentage (%) 10 variants Percentage (%)
A1 (1a, 8a, −9⁎,
22, 32, 33)
50 A1 (1a, 8a, −9⁎,
22, 32, 33)
33‡
A2 (1a, 8a, −9⁎,
21, 32, 33)
25 A2 (1a, 8a, −9⁎,
21, 32, 33)
27
A3 (1a, 8a, −9⁎,
−21, −22, 32, 33)
5 A4 (1a, 8a, −9⁎,
22, 32-6nt, 33)
12‡
A4 (1a, 8a, −9⁎,
22, 32-6nt, 33)
4 A8 (1a, 8a, 9⁎,
22, 32, 33)
11‡
A5 (1a, 8a, −9⁎,
21, 22, 32, 33)
3 A5 (1a, 8a, −9⁎,
21, 22, 32, 33)
10
A6 (1a, 8a, −9⁎,
22, 31, 33)
3 A3 (1a, 8a, −9⁎,
−21, −22, 32, 33)
2
A7 (1a, 8a, −9⁎,
21, 32, −33)
2 A10 (1a, 8a, −9⁎,
21, 31, 33)
2
A8 (1a, 8a, 9⁎,
22, 32, 33)
2 A6 (1a, 8a, −9⁎,
22, 31, 33)
1
A9 (1a, 8a, −9⁎,
21, 32-6nt, 33)
2 A12 (1a, 8a, −9⁎,
22, 32, −33)
1
A10 (1a, 8a, −9⁎,
21, 31, 33)
1 A13 (1a, 8a, −9⁎,
22, 31, 32, 33)
1
A11 (1a, 8a, 9⁎,
21, 32, 33)
1
The alternatively spliced exons included in a full-length clone are presented and
“−” indicated the exons are excluded. The proportion of the same splice variant
from SHRs and WKYs was compared by a two-sided z-test (‡, pb0.05). n is the
number of clones examined.
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spliced exons and their combinations from SHRs and WKYs
The percentages of individual alternatively spliced exons, exon combinator-
ial profiles and their standard deviations were calculated based on the number of
clones examined. A two-sided z-test was applied to compare the statistical
significance between their proportions from SHRs and WKYs.
2.6. Single-cell reverse transcriptase-PCR
To verify that the recorded HEK293 cells in patch-clamp study were
successfully transfected with both B2 and B31 splice variants, we did single-cell
reverse transcriptase-PCR as described in the previous study [20]. Briefly, after a
cell has been characterized electrophysiologically by the patch clamp method, the
cell was collected into an individual vial containing reverse transcription reaction
mix for first strand cDNA synthesis. Nested PCR reactions were employed tospecifically amplify Cav1.2 amplicons for the identification of the presence of
exons 21 and 22 in agarose gels.
The primers for 1st round of PCR are: RatE18F: 5′-ACACTGCAGGTGA-
AGAGGATG-3′ and RatE25R: 5′-TTTCCCTTGAAGAGCTGGACC-3′. For
nested PCR, the primers used were: RatE20F: 5′-TGCAGTGCCACCGCATT-
GTC-3′ and RatE24R:
5′-TTGGCCCTGTTGATGGCCC-3′. PCR conditions were: denaturation at
95 °C for 45 s, annealing at 55 °C for 1 min and extension at 72 °C for 1 min. A
total of 40 cycles were performed for both the 1st round and nested PCR reactions.
In the nested PCR reaction, the positive control PCRswere performed usingB2 or
B31 plasmid as templates. The expected sizes of the nested PCR products were
367 bp for B2 and 427 bp for B31.
2.7. Construction of full-length Cav1.2 splice variants into pcDNA3
vector
Four full-length rat Cav1.2 clones which represent the splice variants sig-
nificantly changed in SHRs were constructed. These constructs were A4 (1a, 8a,
−9⁎, 22, 32-6nt, 33), A8 (1a, 8a, 9⁎, 22, 32, 33), A5 (1a, 8a, −9⁎, 21, 22, 32, 33)
in pcDNA3.1-vector and B31 (1, 8a, −9⁎, 21, 22, 32, 33) in pcDNA3 vector and
their sequences were verified to be correct by DNA sequencing. The detailed
procedures about the constructions are presented in Supplementary Data. The
construction of B2 (1, 8a, −9⁎, 22, 32, 33) in pcDNA3 was described in our
previous study [19].
2.8. Immunolabeling and Western blot analysis to detect the
expressions of A5 and B31 splice variants in HEK 293 cells
The HEK 293 cells were transfected with A5 or B31 splice variants together
with rat β2a, α2bδ, and T antigen using a calcium–phosphate mediated method
and the immunostaining was performed as described previously [21]. Three
primary antibodies (1:200) (Sigma-Aldrich, Inc. Saint Louis, Missouri, USA)
usedwere either anti-exon 1a or anti-exon 1 antibodies, or anti-panα1C antibody
Fig. 3. Comparisons of the individual alternatively spliced exons in heart 1–50
cDNAs from 4.5-month SHRs and WKYs. Exon 8a was down-regulated 16%
from 73% in WKYs to 57% in SHRs. On the contrary, exon 8 was up-regulated
16% fromWKYs (27%) to SHRs (43%). n=116 clones for SHR heart 1–50 and
n=94 clones for WKY heart 1–50. The changes were significantly different
(⁎, pb0.05, z-test). Other exons were not significantly altered (Supplemental
Table S2).
Table 3
The proportions of splice variants in heart 1–50 cDNAs from 4.5-month SHRs
and WKYs
WKY heart 1–50 n=94 SHR heart 1–50 n=116
19 variants Percentage
(%)
25 variants Percentage
(%)
B1 (1, 8a, −9⁎,
21, 32, 33)
29 B1 (1, 8a, −9⁎,
21, 32, 33)
22
B2 (1, 8a, −9⁎,
22, 32, 33)
23 B2 (1, 8a, −9⁎,
22, 32, 33)
13‡
B3 (1, 8, 9⁎,
21, 31, 33)
9 B5 (1, 8, 9⁎,
21, 32, 33)
10
B4 (1, 8a, −9⁎,
21, 32, −33)
7 B8 (1, 8, −9⁎,
21, 32, 33)
8
B5 (1, 8, 9⁎,
21, 32, 33)
5 B31 (1, 8a, −9⁎, 21,
22, 32, 33)
6‡
B6 (1, 8a, 9⁎,
22, 32, 33)
4 B3 (1, 8, 9⁎,
21, 31, 33)
5
B7 (1, 8, 9⁎,
22, 31, −33)
3 B14 (1, 8, 9⁎,
21, 32, −33)
5
B8 (1, 8, −9⁎,
21, 32, 33)
2 B4 (1, 8a, −9⁎,
21, 32, −33)
3
B9 (1, 8, 9⁎,
22, 32, 33)
2 B9 (1, 8, 9⁎,
22, 32, 33)
3
B10 (1, 8, 9⁎,
22, 32, −33)
2 B32 (1, 8a, −9⁎,
22, 31, 33)
3
B11 (1, 8a, −9⁎,
21, 31, 33)
2 B33 (1, 8a, 9⁎,
21, 32, 33)
3
B12 (1, 8a, −9⁎,
22, 32-6nt, 33)
2 B20 (1, 8, −9⁎,
21, 32-6nt, 33)
3
B13 (1, 8a, −9⁎,
21, 32-6nt, 33)
2 B10 (1, 8, 9⁎,
22, 32, −33)
2
B14 (1, 8, 9⁎,
21, 32, −33)
1 B11 (1, 8a, −9⁎,
21, 31, 33)
2
B15 (1, 8, −9⁎,
21, 32, −33)
1 B12 (1, 8a, −9⁎,
22, 32-6nt, 33)
2
B16 (1, 8a, −9⁎,
22, 32, −33)
1 B15 (1, 8, −9⁎,
21, 32, −33)
2
B17 (1, 8a, 9⁎,
21, 31, 33)
1 B16 (1, 8a, −9⁎,
22, 32, −33)
2
B18 (1, 8, −9⁎,
22, 32, −33)
1 B24 (1, 8, −9⁎,
22, 32, 33)
2
B19 (1, 8a, −9⁎,
21, 31, −33)
1 B34 (1, 8, −9⁎,
22, 31, 33)
2
B13 (1, 8a, −9⁎,
21, 32-6nt, 33)
1
B19 (1, 8a, −9⁎,
21, 31, −33)
1
B35 (1, 8, −9⁎, 21,
31, 32, −33)
1
B36 (1, 8, 9⁎, 21, 22,
31, 32, 33)
1
B37 (1, 8a, 9⁎, 22, 32, −33) 1
B38 (1, 8, 9⁎, 21,
22, 31, 33)
1
The alternatively spliced exons included in a full-length clone are presented and
“−” indicated the exons are excluded. The proportion of the same splice variant
from SHRs and WKYs was compared by a two-sided z-test (‡, pb0.05). n is the
number of clones examined.
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antibodies (1:500) were either goat anti-rabbit fluorescein isothiocyanate (FITC)-
conjugated (for anti-exon 1a or anti-exon 1 antibodies) or goat anti-rabbit
Rhodamine-conjugated antibodies (for anti-pan α1C antibody). The immuno-
labeled cells were visualized using a laser-scanning confocal microscope (Fluo-
view BX61; Olympus).
For Western blot analysis, HEK293T cells were transfected with 10.2 μg
Cav1.2 splice variants A1, A5, B2 and B31 respectively, together with 6.0 μg rat
β2a, 6.0 μg α2bδ subunits using Lipofectamine™ 2000 kit (Invitrogen™) and
grown for 48 h in 10-cm petri dishes. One fourth of the cells harvested were
lysed with 150 μl Mem-PER® Reagent A (Pierce Biotechnology) supplemented
with 34.8 μg/ml phenylmethylsulfonyl fluoride (PMSF). 8–16 μl of whole-cell
lysates were applied to 4–20% Tris–Glycine Gel (Invitrogen™) and elec-
trophoresed in Tris–Glycine SDS Running buffer. The proteins were transferred
onto PROTRAN® nitrocellulose membranes (Whatman®, Germany). Anti-exon
1 or anti-pan α1C primary antibodies diluted at 1: 200 were applied to the
membranes, followed by incubation with 1:10,000 secondary donkey anti-rabbit
antibody conjugated with horseradish peroxidase (GE Healthcare). The western
blots were developed using Femto Supersignal reagents (Pierce Biotechnology).
2.9. Whole-cell patch clamp electrophysiological recordings of rat
Cav1.2 splice variants
Whole-cell patch clamp technique (MultiClamp 700B, Axon Instruments)
was employed to study the electrophysiology of the transiently expressed Cav1.2
splice variants in HEK 293 cells. Approximately 1:1:1 molar ratios of cDNA for
rat Cav1.2 splice variant, β2a and α2bδ were applied for transfection of HEK 293
cells. In the 35 mm petri dish, 1.65 μg of cDNA of rat Cav1.2 splice variants (A1,
A4, A5, A8, B2 and B31 respectively, or both 1.65 μg B2 and 1.65 μg B31 in the
dominant negative effect study) together with 1.25 μg of rat β2a, 1.25 μg of α2bδ,
and 0.2 μg of TAG (Tantigen) were transiently co-transfected into HEK293 cells
(Human Embryonic Kidney 293 cells) using a calcium–phosphate mediated
method. Transfected HEK293 cells were grown for 36–48 h in 5%CO2 incubator
at 37 °C before patch clamp analysis. The current–voltage relationship, steady-
state activation, steady-state inactivation recording and the data analyses were
performed as described in our previous studies [18,21].
2.10. Electrophysiological recordings of IBa in cardiac myocytes
isolated from SHR and WKY rats
2.10.1. Isolation of single cardiac myocytes
4.5-month SHR and WKY rats were injected intraperitoneally with 1000 IU
heparin and euthanized in a CO2 chamber. The heart was quickly removed and
transferred to an ice-cold Tyrode solution. The aorta was cannulated and theheart was mounted on a Langendorff apparatus. The heart was perfused with
prewarmed (at 37 °C) and oxygenated Tyrode solution containing Protease Type
XIV (Sigma P5147) Collagenase Type I (Sigma C0130) for 10 min until the
heart was flaccid. The ventricles were dissected out, cut into small pieces, and
gently stirred in the Tyrode solution. Isolated cells were filtered and maintained
in an oxygenated KB solution on ice.
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cardiac myocytes
Voltage-clamp experiments for recording SHR and WKY cardiac myocytes
were performed at room temperature (20–22 °C), using the whole-cell patch
clamp technique. Pipets with resistance of 1–2.5 MΩ were used and the series
resistance and capacitive currents were compensated at 70%. To resolve the
currents conducted through L-type calcium channels under voltage clamp, the
bath contained (in mM) the following: N-methyl-D-glucamine (NMG), 155;
HEPES, 10; MgCl2, 1; and Ba
2+, 1.8 (pH 7.4 with MeSO3). The internal solution
contained (in mM): Cs-MeSO3, 120; CsCl, 5; HEPES, 10; EGTA, 10; MgCl2, 1;
MgATP, 4; TEA-OH, 20; Sodium phosphocreatine, 5 and ryanodine (BIOMOL),
0.005 (pH 7.2 with CsOH). The current–voltage (I–V) relations were obtained
from a holding potential of −80 mV, 0.5 s depolarizing pulses to different
membrane potentials (10 mV increments from −60 mV to +50 mV). The I–V
curves were fitted by I / Imax=Gmax(V−Erev) / {1+exp[(V−V1/2) /kI–V]}, where I
is the test-pulse current, Imax is the normalization peak current, Gmax=maximum
conductance, Erev= reversal potential, V1/2=voltage at 50% of Ba
2+current
activation, and kI–V=slope factor. The steady-state inactivation curves were
obtained from experiments by stepping from a holding potential of −80 mV to a
30-ms normalizing pulse to 0 mV followed by a family of 5-s-long prepulses
from −100 to 20 mV. A 104-ms test-pulse to 0 mV was recorded finally. Each
test-pulse was normalized to the maximal current amplitude of the normalizing
pulse. The data for inactivation curves were fitted with a simple Boltzmann
function: I / Imax=(A1−A2) /{1+exp[(V−V1/2inact) /k]}+A2, where I is the test-
pulse current, Imax is the normalization current,A1 is initial current amplitude, A2 is
final current amplitude, V is the membrane potential of the conditioning pulse,
V1/2inact is the potential for half-inactivation, and k is the slope factor.
For pharmacological study, nifedipine (Sigma) was dissolved in Me2SO to
make a 10 mM stock solution and stored at −20 °C. Nifedipine at 5 μM was
freshly prepared in bath solution from stock. Cardiac myocytes from SHRs and
WKYs were held at −80 mVand then depolarized at 0 mV testing potential for
0.5 s. All experiments involving nifedipine were conducted as much as possible
in the absence of light.Fig. 4. Distributions of 42 splice variants of Cav1.2 in 4.5-month SHR andWKY
hearts. A total of 42 splice variants with distinct exon combinatorial profiles
have been identified in 4.5-month SHR and WKY hearts. Twenty-three splice
variants were identical in both WKY and SHR hearts. However, WKYs
contained 7 unique splice variants and SHRs contained 12 variants different
from those in WKYs.3. Results
3.1. Evaluations of the pathophysiological characteristics of
SHRs and WKYs
Table 1 shows the pathophysiological characteristics of 3-,
4.5- and 8-month SHRs and WKYs such as blood pressures
and heart weight-to-body weight ratios. SHRs had significantly
higher (N60 mmHg) systolic blood pressure (pb0.01) and about
20% (pb0.01) increase in the heart weight-to-body weight
ratio relative to age-matched WKYs. In addition, left ventricle
weight-to-body weight ratio was 2.7±0.30 mg/g for 4.5-month
SHRs and 2.0±0.26 mg/g for 4.5-month WKYs representing a
35% increase in left ventricle weight-to-body weight ratio in
SHRs than WKYs. These results confirmed that high blood
pressure was fully developed and heart hypertrophy was ini-
tiated in 3-month SHRs and maintained up to 8 months in age.
3.2. Comparison of expressions of alternatively spliced exons
at single locus or in combination in heart 1a–50 cDNAs
Exon-specific colony PCRs and DNA sequencings were per-
formed to identify the alternatively spliced exon at individual
locus of each Cav1.2 full-length clone. Comparison of the ex-
pression levels of each splice locus between 4.5-month SHRs
and WKYs showed that exon 9⁎ was significantly up-regulated
from 3% in WKYs to 11% in SHRs (Fig. 2C). The agarose
electrophoresis gel shown in Fig. 2B revealed the larger PCRproduct containing the additional exon 9⁎ that was confirmed by
DNA sequencing. The other 8 alternatively spliced exons were
not significantly altered (Fig. 2C and Supplementary Table S2).
In line with the result from our previous study [19], there is no
clone in the heart 1a–50 cDNAs containing exon 8. In addition,
the rat counterparts of human alternate exon 10⁎, exon 45⁎ and
exon 45 have not been identified in rats thus far [6,18,22], and
we did not find these 3 exons in the 402 full-length rat Cav1.2
clones in this study.
Although at the single alternative splicing locus, only the
proportion of exon 9⁎ showed a significant 3.7-fold increase in
SHR heart, the combinatorial patterns of alternatively spliced
exons of heart 1a–50 Cav1.2 channels were altered significantly
in 4.5-month SHRs than in WKYs (Table 2). While exon com-
binatorial profile A1 showed a decrease of 17% in SHR hearts,
A4 was up-regulated from 4% in WKYs to 12% in SHRs, and
A8 was increased from 2% in WKYs to 11% in SHRs. All the
changes in expression levels of A1, A4 and A8 were statistically
significant (pb0.05, z-test). In addition, there were 3 unusual
alternatively spliced variants (aberrant variants) in heart 1a–50
that either exclude or include both mutually exclusive exons 21
and 22 (A3 and A5); or include another pair of mutually ex-
clusive exons 31 and 32 (A13). The aberrant channels com-
prised 8% of Cav1.2 transcripts in WKY heart 1a–50 (A3 and
A5) and 13% in SHR heart 1a–50 (A3, A5 and A13).
3.3. Comparison of expressions of alternatively spliced exons
at single locus or in combination in heart 1–50 cDNAs
Only the proportions of mutually exclusive exons 8a and 8
were found significantly changed in heart 1–50 cDNAs (Fig. 3
and Supplementary Table S2). However, the differences in exon
combinatorial profiles between SHR and WKY heart 1–50
cDNAs were more pronounced and widespread (Table 3). The
significant changes in alternative splicing profile were found in
B2, a decrease of 10% in SHRs, and the expression of 6% of the
novel B31 splice variant. It seemed the reduced proportion of
B2 in SHRs was partially replaced by the increased percentage
Fig. 5. Up-regulation in the percentages of splice variants containing both
mutually exclusive exon 21 and exon 22 in 4.5-month SHRs in comparison to
age-matched WKYs. A. Exemplar PCR results showing the increased per-
centages of (exons 21 +22) in SHR heart 1–50 cDNAs in comparison to the
WKY one. The upper primer is in constitutive exon 17 and lower primer is
specific for exon 22 (primer Nos. 17 and 18). Colony PCR results with 2 different
sizes were seen in SHR heart 1–50 (upper panel) while bands with identical size
were observed in WKY heart 1–50 (lower panel). The sequencing results
confirmed the higher bands contained both exons 21 and 22, i.e. (+21 +22); while
the lower bands contained mutually exclusive exon 22 alone, i.e. (−21 +22). The
negative controls using untransformed colonies as templates are indicated as
“−ve”. B. Comparison of the percentages of splice variants containing (exons 21
+22) in the four full-length cDNAs groups from SHRs and WKYs. About 8%
transcripts containing (exons 21 +22) were found in SHR heart 1–50, but no
splice variants containing (exons 21 +22) were identified in WKY heart 1–50
(⁎⁎, pb0.01, z-test). In addition, higher (but not significantly different) per-
centages of splice variants containing (exons 21 +22) were found in SHR heart
1a–50 (10%) than in WKY heart 1a–50 (3%) (#, p=0.064, z-test).
Fig. 6. Immunostaining for A5 and B31 Cav1.2 channel splice variants
transiently expressed in HEK293 cells. The protein expressions of A5 (1a, 8a,
−9⁎, 21, 22, 32, 33) and B31 (1, 8a, −9⁎, 21, 22, 32, 33) splice variants which
contain both mutually exclusive exons 21 and 22 were demonstrated by im-
munolabelling with anti-exon 1a, anti-exon 1 and anti-pan α1C antibodies. HEK
293 cells co-transfected with A5 (1a, 8a, −9⁎, 21, 22, 32, 33) splice variant, rat
β2a and α2δ subunits were stained with anti-exon 1a (green, FITC), (A–C), and
anti-pan α1C antibodies (red, Rhodamine), (D–F); HEK 293 cells co-transfected
with B31 (1, 8a, −9⁎, 21, 22, 32, 33) splice variant, rat β2a and α2δ subunits were
stained with anti-exon 1 (green, FITC) (G–I) and anti-pan α1C antibodies (red,
Rhodamine) (J–L). The non-transfected HEK 293 cells were not labeled by the
immunostaining (C, F, I and L). Bars, 20 μm.
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exon 22 alone in B2. Overall, WKY heart 1–50 cDNAs com-
prised 19 splicing combinatorial profiles while SHR heart 1–50
cDNAs had 25 (Table 3). Among these 25 combinatorial pro-
files, 15 were identical to those found in WKYs while 10 were
unique to SHRs (B20, B24 and B31–B38; Table 3). In addition,
SHR heart 1–50 contained 4 aberrant splicing combinatorial
profiles which included both mutually exclusive exons 21 and
22 (B31, B36 and B38), or both mutually exclusive exons 31
and 32 (B35 and B36). The aberrant profiles accounted for
about 9% of Cav1.2 transcripts in SHR heart 1–50 but none in
WKY heart 1–50.
3.4. Ratios of Cav1.2 transcripts containing either exon 1a or
exon 1 were not significantly changed in 3- and 8-month SHR
and WKY ventricles
The cDNA levels of exon 1a and exon 1 containing Cav1.2
channels in rat ventricles from 3-month and 8-month SHRs or
WKYs were evaluated by quantitative real-time PCR, revealing
a 13.4- to 16-fold higher expression of exon 1a over exon 1transcripts in SHRs and WKYs (Supplementary Table S3).
However, there was no significant difference in the ratios of
expression of exon 1a/exon 1 of Cav1.2 transcripts obtained
from 4 groups of ventricles of 3-month and 8-month SHRs or
WKYs (pN0.05; one-way ANOVA and Tukey test, Supple-
mental Table S3).
3.5. Distributions of 42 exon combinatorial profiles of Cav1.2
in SHR and WKY hearts
There were 42 distinct exon combinatorial profiles identified
in heart 1a–50 and heart 1–50 cDNAs of 4.5-month SHRs and
WKYs. A total of 30 profiles were identified in WKY hearts
while 35 were found in SHRs. While 23 exon combinatorial
profiles were identical in both WKYs and SHRs, 7 were unique
in WKYs and 12 in SHRs (Fig. 4). Hence, under hypertensive
cardiac hypertrophy, certain splice loci varied significantly
when analyzed individually but more obvious changes were
observed in their full-length combinatorial profiles.
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In SHR hearts, there was an increase in the generation of
aberrant splice variants which either included or excluded the
pairs of mutually exclusive exons. Among the 42 exon com-
binatorial profiles, 7 were aberrant splice variants: A3, A5, A13,
B31, B35, B36 and B38 (Tables 2 and 3). It is noteworthy that
while all 7 aberrant splice variants were found in SHRs, only 2
were found in WKYs (A3 and A5) and there were no aberrant
variants found in WKY heart 1–50. The aberrantly spliced
Cav1.2 channels were increased from 8% inWKYheart 1a–50 to
13% in SHR heart 1a–50, and from none in WKY heart 1–50 to
9% in SHR heart 1–50. Interestingly, the predicted proteins
encoded by these aberrant variants are all in-frame, without any
premature stop codon suggesting that these aberrantly spliced
mRNAswould survive the process of nonsense-mediatedmRNAFig. 7. Western blots of A1, A5, B2 and B31 Cav1.2 channel splice variants and cur
blotting study using anti-exon 1 and anti-pan α1C antibodies showed that the proteins
sizes of these Cav1.2 splice variants are ∼240 kDa. Multiple small bands in A5 loadin
B. Current–voltage recordings of 5 rat Cav1.2 splice variants significantly altered in h
(upper panel) and current–voltage relationships of the splice variants (lower panel) a
1.0 s depolarizing pulses to different membrane potentials (10 mV increments from −
Table 4. In contrast to A1, A4 and A8 splice variants which show recorded current trac
exclusive exons 21 and 22 showed no currents detected in I–V recording (n=18 fodecay (NMD) [23,24] and express their proteins. However, as
shown later, two of the aberrant splice variants tested in this study
demonstrated they were expressed but not functional when
heterologously expressed in HEK 293 cells.
Out of the 7 aberrant splicing profiles, 4 of them (A5, B31,
B36 and B38) contained both mutually exclusive exons 21 and
22 (Tables 2 and 3). Interestingly, the proportions of aberrant
Cav1.2 channels containing exons 21 and 22 were higher in both
SHR heart 1a–50 and heart 1–50 cDNAs than in their WKY
counterparts (Fig. 5). SHR heart 1a–50 comprised about 10% of
Cav1.2 channels containing exons 21 and 22 while WKY hearts
only 3%. Similarly, SHR heart 1–50 contained significantly
higher number of Cav1.2 channels including both exons 21 and
22 than in WKY controls (8% in SHRs to none in WKYs,
pb0.01). To evaluate whether such aberrant channels could
be expressed and be functional, we transfected two of aberrantrent–voltage recordings of A1, A4, A8, A5 and B31 splice variants. A. Western
of B31, B2, A5 and A1 splice variants were expressed. The expected molecular
g lane stained by anti-pan α1C antibody suggested these are degraded products.
ypertension (A1, A4, A8, A5 and B31). Exemplar current–voltage (I–V) pulses
re shown. The I–V relations were obtained from a holding potential of −80 mV,
50 mV to +50 mV). V1/2 values of A1, A4, A8 splice variants are presented in
es upon different voltage stimulations, A5 and B31 which contain both mutually
r A5; n=26 for B31).
Table 4
Parameters of current–voltage relationships, steady-state activation and steady-
state inactivation of A1, A4 and A8 splice variants
Splice variants V1/2 (mV) Erev (mV) V1/2 act (mV) V1/2 inact (mV)
A1 (1a, 8a, −9⁎,
22, 32, 33)
−13.26±0.75 45.55±0.45 8.8±2.14 −34.53±1.33
A4 (1a, 8a, −9⁎,
22, 32-6nt, 33)
−18.28±0.92 ‡ 44.08±0.84 1.70±1.52‡ −37.41±0.65
A8 (1a, 8a, 9⁎,
22, 32, 33)
−19.67±0.89 ‡ 42.8±0.69 0.15±2.33‡ −35.99±1.72
‡, pb0.01 when compared to the A1 variant (Student's t-test). The numbers of
tested cells are indicated in Figs. 7 and 8.
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munolabelling of these transfected HEK 293 cells with either
anti-exon 1a or anti-exon 1, or anti-pan α1C antibodies showed
strong fluorescent signals detected on the plasma membrane
while weaker punctated signals were detected in the cytoplasm
(Fig. 6), indicating that the proteins of A5 and B31 variants
were expressed. Western blots using anti-exon 1 and anti-panFig. 8. Activation and steady-state inactivation properties of A1, A4 and A8 splice
variants evoked by repolarizations to−50 mVafter depolarizing test-pulses at −40 m
steady-state inactivation (SSI) recording. B. and C. The ensemble of activation and
recording for activation and SSI recording. The values of V1/2act and V1/2inact for eac
curves indicated the theoretical “window currents” [25,42] for the 3 variants. D. Pl
potentials to show the values of “window currents” for A1, A4 and A8 splice varianα1C antibodies confirmed that A5 and B31 aberrant variants
were expressed (Fig. 7A). Positive controls using the functional
Cav1.2 cDNAs encoded by splice variants A1 and B2 verified
the correct molecular size of the A5 and B31 aberrant proteins.
However, A5 and B31 Cav1.2 channels expressed in HEK 293
cells were non-functional as no inward current was recorded
from these variants when co-expressed with rat β2a and α2bδ
(n=18 for A5; n=26 for B31). In contrast, IBa was recorded
from other Cav1.2 splice variants, A1, A4 and A8, in elec-
trophysiological recordings performed in parallel (Fig. 7B).
3.7. Distinctive current–voltage relationships and steady-state
activation of Cav1.2 splice variants
To assess possible functional importance in the changes
of proportions of Cav1.2 splice variants, we evaluated the elec-
trophysiological properties of the other three splice variants that
also showed significant changes in heart, namely A1, A4 and
A8. We limited our investigations for the following threevariants. A. Upper panel shows exemplar tail currents of A1, A4 and A8 splice
V, 0 mV, 40 mVor 90 mV; lower panel shows exemplar recording traces of their
SSI properties of A1, A4 and A8 splice variants obtained from traditional tail
h splice variant are presented in Table 4. Superimposition of activation and SSI
otting the negative product of activation and SSI curves at different membrane
ts.
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transcripts than the heart 1–50 (Supplemental Table S3), hence
the changes in A1, A4 and A8 in heart 1a–50 would represent
the dominant changes observed in hypertensive hearts; (2) the
biophysical property of B2 has been evaluated in pharmacolo-
gical studies by others [9,10]; and (3) the A5 and B31 are
aberrant variants shown to be not functional. Whole-cell patch
clamp electrophysiological recordings showed that the I–V
relations of the splice variants A4 and A8 were hyperpolarized
shifted by about 5 mV and 6.4 mV when compared with the
heart 1a–50 dominant variant A1 (Fig. 7A). Both V1/2 values of
A4 and A8 splice variants were significantly different from that
of A1 variant (pb0.05), while the reversal potentials for all the 3
splice variants were similar (Table 4).
To further examine the extent by which exon combinatorial
profiles may affect the voltage-dependence of activation, we per-
formed tail-current analysis of the activation process. The V1/2act
values were significantly shifted in the hyperpolarized direction
by 7.1 mV for A4 and by 8.7 mV for A8 than the dominant A1
variant (Fig. 8 and Table 4). However, the steady-state inacti-
vation properties of A4 and A8 splice variants exhibited no sig-
nificant difference in V1/2inact when compared to A1 (Fig. 8 and
Table 4). To determine whether the “window currents” of A4 and
A8 might be different to A1 due to their hyperpolarized shifts in
V1/2act values but not to changes in V1/2inact values, we calculated
the theoretical “window currents” of A1, A4 and A8 by multi-Fig. 9. Dominant negative effect of B31 Cav1.2 channel aberrant variant on normal B2
potentials (−60mV to 100mV) shows the amplitudes of currents recorded in HEK293
B31) variants togetherwith ratβ2a andα2bδ subunits. B. Single-cell RT-PCR results fo
HEK293 cell. Control PCRswere performed using B2 or B31 plasmid as templates for
PCR products were 367 bp for B2 and 427 bp for B31. Single-cell RT-PCR of 9 H
recordings showed two PCR products of sizes that correspond to the transfected B2plying their activation curve values by their corresponding inac-
tivation curve values [25–27]. A8 exhibited a larger window
current (3% of its peak IBa) than A1 (1% of its peak IBa) due to the
hyperpolarized shift inV1/2act values by∼8.7mV (Fig. 8C andD).
However, the window currents of A4 and A1 were similar (1% of
their relative peak IBa) as the foot regions of their activation curves
were largely overlapping (Fig. 8B and D).
3.8. Dominant negative effect exerted by aberrant splice
variant B31 on B2 function
The expression of aberrant non-functional Cav1.2 variants
such as A5 and B31 suggests that RNAs or/and proteins of these
aberrant variants may affect the expression of functional chan-
nels in a dominant negative manner through competition for
factors involved in Cav1.2 channels transcription, translation,
protein folding, transport, phosphorylation or by other physio-
logical regulatory mechanisms. To test this hypothesis, we ex-
amined the tail-current densities of the normal B2 variant when it
was transfected alone or co-transfected with B31 into HEK293
cells. As shown in Fig. 9A, the current density obtained from tail-
current recording inHEK293 cells co-transfectedwith (B2+B31),
rat β2a and α2bδ subunits were markedly reduced when compared
to the control group in which HEK293 cells were transfected with
B2, rat β2a and α2bδ subunits. The single-cell RT-PCR from the
recorded HEK293 cells confirmed that both B2 and B31Cav1.2 splice variant. A. Tail current recording obtained from different prepulse
cells transfected with B2 variant together with ratβ2a andα2bδ subunits, or (B2+
r verifying the successful transfection of B2 andB31 variants together into a single
showing the correct amplicon sizes for reference. The expected sizes of the nested
EK293 cells that exhibited IBa currents during whole-cell electrophysiological
and B31 Cav1.2 channel transcripts (lanes 1–9).
Fig. 10. Electrophysiological and pharmacological studies for SHR and WKY cardiac myocytes. A. Exemplar I–V test-pulses and I–V relationships of cardiac
myocytes isolated from SHRs and WKYs. B. Exemplar SSI recording and SSI properties of cardiac myocytes isolated from SHRs and WKYs. The values of V1/2 and
V1/2inact for SHRs and WKYs cardiac myocytes are presented in Table 5. C. Effect of 5 μM nifedipine on WKYand SHR cardiomyocytes. The holding potential was
−80 mV while IBa was recorded at a test potential of 0 mV in the presence or absence of nifedipine. The level of inhibition was obtained by normalizing to the control
current amplitude without nifedipine treatment. Data represent the remaining currents compared with peak current without drug treatment. IBa–WKY=40.60 (±4.805)
%, IBa–SHR=45.88 (±3.585) %, p=0.418, unpaired t-test.
Table 5
Parameters of current–voltage relationships and steady-state inactivation of
L-type calcium channels in cardiac myocytes from SHRs and WKYs
Cardiac myocytes V1/2 (mV) Erev (mV) nI–V V1/2 inact (mV) ninact
SHRs −26.38±0.87 45.26±1.61 12 −36.43±0.92 10
WKYs −30.16±0.68 49.33±1.96 8 −38.87±0.65 7
n = number of tested cells. No significant differences were found in I–Vand SSI
properties between the cardiac myocytes from SHRs and WKYs.
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9B). Therefore, it is obvious that aberrant splice variant B31
exerted the dominant negative effect on normal B2 variant in the
heterologous HEK293 cells expression system.
3.9. Electrophysiological and pharmacological studies for
SHRs and WKYs cardiac myocytes
L-type calcium channels in heart ventricles consist of mainly
the Cav1.2 calcium channels and a very small portion of the
Cav1.3 channels [28,29]. To examine the behaviors of the overall
Cav1.2 channels consisting of all the existing splice variants in
heart muscle cells, we examined the electrophysiological
properties of L-type calcium channels in cardiac myocytes
isolated from the left ventricles of 4.5-month SHR and WKY
rats. Our results showed that generally the L-type calcium
channels in cardiac myocytes from these two rats displayedmodest differences in the current–voltage relationships and in
the voltage-dependent steady-state inactivation properties. The
values of V1/2 and V1/2inact were −26.38 mVand −36.43 mV for
SHRs, and −30.16 mVand −38.87 mV for WKYs (Fig. 10 and
Table 5). Similarly, the sensitivity of the L-type calcium channel
currents blockade by nifedipine (5 μM) recorded at a holding
potential of −80 mVwas not significantly different. The average
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of the control current amplitude after application of nifedipine,
and to 45.88 (±3.585)% of the control current amplitude in
SHRs cardiac myocytes, (p=0.418), (Fig. 10C).
4. Discussion
This study revealed the complex alterations in the alternative
splicing of Cav1.2 channels in SHR cardiac hypertrophy. Pre-
vious studies have reported that dopamine receptors, sarco/
endoplasmic reticulum Ca2+ATPases and plasma membrane
Ca2+ATPases genes were subjected to either exon-switching or
alteration in the expression level of the isoforms under hy-
pertensive conditions [30–32]. Here, we further demonstrated
the dynamic changes in the alternative splicing profiles of
Cav1.2 channels both at single loci and in their combinatorial
profiles. Currently, the technical limitation in isolating and se-
quencing one-molecule Cav1.2 variant protein (∼240 kDa)
precludes the determination of their individual molecular id-
entities in native tissues. Hence the combinatorial splicing
profiles of Cav1.2 transcripts identified in this study will pro-
vide an essential alternative for understanding their proteomic
diversity in SHR hypertrophied hearts.
4.1. Implications of altered functional characteristics of
dominant Cav1.2 splice variants
It has been reported that the promoter for transcribing exon
1a is activated mainly in neonatal cardiomyocytes but not in
cardiac fibroblasts, H9C2 cells, or human aorta-vascular smooth
muscle [33–35]. Moreover, heart 1a–50 Cav1.2 channels were
also reported to be expressed in isolated cardiac myocytes [36].
These studies suggest that heart 1a–50 Cav1.2 channels are
expressed in cardiomyocytes. Previous studies have shown that
exon 9⁎ is rarely expressed in rat ventricles [21] and is un-
detectable in human atrial cardiomyocytes [12]. In agreement
with these reports, we found that exon 9⁎ represented only 3%
in heart 1a–50 in WKY but the expression was increased to
11% in SHR heart 1a–50. Consequently, the full-length splicing
combinatorial profile A8 containing exon 9⁎ was increased
from 2% in WKY heart 1a–50 to 11% in SHR heart 1a–50. The
A8 variant encoding Cav1.2 channels that displayed larger
window currents and activation at more hyperpolarized voltages
may potentially allow for a larger driving force to increase
magnitude of ICaL which is often seen in hypertrophied cardiac
myocytes [37]. In SHR heart 1a–50, the combined increase in
expression of A4 and A8 was 17% while correspondingly A1
decreased by 17%. The 5–6.4 mV hyperpolarized shift in the I–
V relations attributable to A4 and A8, and compared to A1, may
result in a predicted overall small hyperpolarized shift. How-
ever, we did not observe the same hyperpolarized shift in native
cardiac myocytes of SHR cardiac myocytes but instead a small
∼3.8 mV depolarized shift in I–V was observed over WKYs,
while the I–V relationships of the Cav1.2 channels recorded in
6 month old SHR and WKY cardiomyocytes were similar [38].
Whether the remodelling of the Cav1.2 channels generating
different subsets of combinatorial profiles may vary over thetime course of the development of cardiac hypertrophy or heart
failure would require much more detailed and careful mole-
cular and electrophysiological experimentations. The opposite
shifts in I–V relationships of the A4 and A8 variants to what
was actually recorded in ventricular muscles suggest a possible
mechanism to remodel Cav1.2 channels to compensate for un-
known factors that depolarized shift the activation potential of
the Cav1.2 calcium channels.
As discussed in our previous study [19], heart 1–50 cDNAs
could be derived from multiple cell types like cardiomyocytes,
cardiac fibroblasts, and vascular smooth muscle cells and its
functional importance can be implied from the classic Timothy
syndrome caused by the mutation in exon 8which is named exon
8A by Splawski et al. in their report [39]. Two changes in SHR
heart 1–50 cDNAs should be highlighted. First, the 16% up-
regulation in exon 8 may affect the pharmacological effects of
calcium channel blocker dihydropyridines (DHPs) on these
subset channels as it was previously reported that exon 8a
and exon 8 regulated the sensitivity of Cav1.2 channels to DHPs
differently [9]. Interestingly, a recent report also showed that two
out of 39 human ischemic hearts examined showed unusually
higher expression level of exon 8 in the left ventricles [17].
However, we did not observe a significant difference in
nifedipine blockade when we applied the 5 μM nifedipine on
native cardiac myocytes isolated from SHR or WKY rats (Fig.
10C). One possible reason is that the change in exon 8
expression was mainly from other heart cells like cardiac
fibroblasts or vascular smooth muscle cells rather than cardiac
myocytes. Another reason is likely that the overall level of exon
8 expression is very low as the change was observed in the heart
1–50 cDNAs. This group of exon 1-containing Cav1.2 channel
cDNAs accounted for less than 7% of the total Cav1.2 cDNAs
(Supplementary Table S3). Secondly, Cav1.2 channels contain-
ing both exons 21 and 22 were found to be significantly
increased in SHR heart 1–50 cDNAs and as a result, the aberrant
splice variant B31 was generated in SHRs but not in WKYs. It
will be interesting to identify which cells are involved in the up-
regulation of B31 expression in SHRs. Future experiments
carried out on the isolated cardiomyocytes, cardiac fibroblasts,
and vascular smooth muscle cells will be helpful in providing an
explanation.
4.2. Relevance of aberrant Cav1.2 alternative splicing isoforms
to cardiac hypertrophy
Interestingly, the aberrantly spliced Cav1.2 channels were
increased from 8% in WKY heart 1a–50 to 13% in SHR heart
1a–50, and from none in WKY heart 1–50 to 9% in SHR heart
1–50, and two of them, A5 and B31, demonstrated to form non-
functional channels. One possible explanation for their non-
functionality is that the topology of the channels may have been
affected by the inclusion of both exons 21 and 22. Exon 21 or
exon 22 forms the transmembrane IIIS2 segment and two copies
of these may invert the topology of the downstream sequences.
In addition, we showed that B31 exerted dominant negative
effects on normal B2 variant when they are co-expressed in
HEK293 cells. It is not clear what the mechanism is for this
129Z.Z. Tang et al. / Biochimica et Biophysica Acta 1783 (2008) 118–130dominant negative effect. The RNAs and proteins of aberrant
variants would compete with normal variants during the whole
process for functional Cav1.2 channel synthesis, from transcrip-
tion, translation to protein modification. Another explanation is
that the B31 aberrant channels directly compete for the β and
α2δ subunits as they have been shown to be expressed on the
cell surface and they produce robust amount of proteins as
detected by Western blot analysis. However we cannot exclude
that the unfolded protein response system may have been ac-
tivated if the B31 aberrant channels behaved like truncated cal-
cium channels [40,41]. The overall effect of these aberrant
channels is likely to act in a dominant negative manner in vivo
to homeostatically regulate the expression level and activities of
Cav1.2 channels in the hypertrophied cardiomyocytes.
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